Eight mongrel puppies were studied at intervals of a few weeks. Lignocaine 4mg/kg was infused over 60 seconds. Frequent samples were taken over 30 minutes for plasma lignocaine assay. Initially the concentrations were significantly higher in the oldest group (178)(179)(180)(181)(182)(183)(184)(185)(186)(187)(188)(189)(190)(191) days) but after 10 minutes the youngest group (3-16 days) had significantly higher levels than the other groups.
pressure, end-expired C02 and oesophageal temperature were measured. Body temperature was maintained by wrapping the animal in cotton wool and using a heater.
Lignocaine was infused through an external jugular cannula, 4mg/kg in 6ml given by constant infusion over 60 seconds. Prior to the lignocaine infusion 20mllkg of Hartmann's solution in 5 per cent dextrose was given to ensure that hypovolaemia did not result from sampling. The infusion was always completed at least 10 minutes before the experiment began.
An arterial line was established with a 22 gauge Medicut cannula in the femoral artery. The method shown in Figure 1 was used for sampling. About five seconds before sampling time blood was slowly withdrawn through the distal three-way tap so that freshly drawn blood filled the line. At the sampling time the proximal three-way tap was opened and the sample withdrawn by a second operator. The proximal tap was then closed and the remaining blood was flushed back until the line was clear. The dead space in the proximal tap was cleared of blood with a cotton wool stick to avoid mixing of the sample with previously drawn blood. Using two operators, rapid and accurately timed sampling could be achieved. After collection, the blood was centrifuged and the plasma removed with a Pasteur pipette. The plasma was stored in glass vials at -20 QC until required for extraction and analysis.
Analysis of lignocaine hydrochloride in plasma was conducted using high performance liquid chromatography, with UV detection at 205nm (Perkin Elmer L-75 variable wavelength detector). Chromatography was performed using a CS column (Dupont, Zorbax CS) and a mobile phase consisting of methanol and water (6S:32). The mobile phase was buffered with 0.21170 orthophosphoric acid, the pH being adjusted to 7.0 with ammonia. The mobile phase elution rate was 1.5mllminute. Bupivacaine hydrochloride was used as the internal standard and total chromatography time was 15 minutes. All plasma levels were expressed as !lg/ml of lignocaine hydrochloride. Coefficients of variation calculated at 0.5, 1.0 and S.O !lg/ml were 3.131170 (n=5), 1.601170 (n=7) and 1.391170 (n = 7) respectively.
The plasma concentration (Cp) versus time (t) data after the intravenous administration of lignocaine was fitted to the following polyexponential equation:
Cp=~ r = I Cie -Ai t using the computer program AUTOAN. 4 In this question, n is the number of exponents required to describe the plasma concentrationtime data, Ci is a zero time intercept and Ai is a disposition rate constant. For a biexponential equation (n = 2), the parameters, Cl' and {3, are commonly used to represent A I and A2. AUTOAN is a Fortran IV computer program which can be used to analyse data described by pharmacokinetic models involving either first order or Michaelis-Menten kinetics. AUTOAN is used in conjunction with the nonlinear regression program NONLIN. 5 AUTOAN calculates the minimum number of exponents required to adequately describe the data. Variations in the accuracy of the analytical technique and the effects of very small and very large values are overcome by weighting each datum point with a squared reciprocal.
Using weighted plasma concentration points, the rate constants, kl2 and k21 which govern drug movement between compartments and kJO governing elimination from the central compartment were calculated ( Figure 2 ). Other parameters, such as volumes of distribution were calculated from these rate constants using standard pharmacokinetic equations. 6 The criteria used to assess adequate fit of the data to the model were those employed by Bloedow et al. 7 Comparison of groups was conducted with ML TCOMP which conducts a multiple t-test. Significance levels were set at P<0.05.
-Representation of drug movement and rate constants between compartments. Table 1 defines the age groups of the dogs studied. The mean plasma concentrationtime profiles for the four age groups are shown in Figure 3 . The mean plasma concentrations for each age group were compared at each sampling time. At 10 seconds the mean concentration for Group 4 (178-191 days) was significantly higher than all other groups. There was no significant difference between 20 seconds and 9 minutes. After this the plasma concentration in the youngest age group (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) days) was significantly higher than all others.
RESULTS
The mean maximum concentrations for each group are summarised in 
Pharmacokinetic parameters
The data for the dogs fitted a two compartment model, except one which best fitted a three compartment model. The results for the latter dog were not included because the computer program used was for a two compartment analysis.
Drug movement between the compartments is governed by the constant K 12 and K21 and the elimination from the central compartment by KIO. The rate constants for the seven dogs fitting the two compartment model are given in Table 3 .
For the distribution rate constants, K21 and K12, there is no significant difference between any of the age groups. The mean elimination rate constant, klO, for group 1 is significantly different from all others. A significant difference also occurs between group 2 and group 4.
The derived pharmacokinetic constant CI", f3, and v~lum.e of distribution (V f3) are summansed III Table 4 . Cl" and f3 by definition are the slopes of the lines of best fit for the two phrases of the drug distribution profile. Hence, Q' and {3 represent the rate of drug movement during these phases. It is assumed that Q'reflects the rate of initial drug distribution and that {3 reflects the overall rate of drug movement while both distribution and elimination processor are occurring. The volumes of distribution given in Table 4 have been calculated during the {3 or second phase of drug movement. It should be noted that volumes of distribution are a function of time.
From Table 4 it can be seen that there is no significant difference in the mean Q' values for each age group. This was obvious in Figure 3 , which illustrates the similarity of the initial phase in all age groups.
The mean value {3 value calculated for the youngest age group was significantly different from the others (P<0.05). The increase in mean {3 values reflected a shorter half-life for the second phase with increasing age. Half-lives calculated from the mean {3 values were 26.7, 14.4, 14.1 and 1l.6 minutes respectively. There was a strong positive correlation between age and {3 values (r =0.707 P<O.OOI) (Figure 4) .
The mean apparent volumes of distribution (V (3) were not significantly different.
DISCUSSION
This investigation was set up to fill a gap in knowledge concerning pharmacokinetics of lignocaine by studying a group of puppies at four stages during development until they were nearly six months old.
Although the initial plasma levels in all groups were very high (>20 JAg/ml), no signs of lignocaine toxicity were observed, probably because the animals were anaesthetised. Levels of a similar magnitude have been reportgd by other workers studying lignocaine kinetics with rapid early sampling. 9 -11 It is not clear why the plasma concentrations in the oldest age group was higher than when the dogs were younger. The mixing volume may be smaller or tissue clearance may be greater. The rapid decline from the peak concentration ( Figure 3 ) was similar to that observed by others in humans 10, 11 and dogs. 8 ,9 The initial phase is mixing with some distribution_ It has been shown in adult dogs that distribution is not complete until 20 minutes 8 so that the second phase may be a mixture of distribution and elimination. The mean half-life of this phase for all pups studied intravenous lignocaine administered to humans.IO,1I The half-life of this initial phase would be dependent on cardiac output. The shorter half-life calculated for young dogs compared with adult humans suggests more rapid circulatory mixing and drug distribution due to relatively greater cardiac output in young subjects. The higher plasma levels during the second phase for the younger dogs suggests slower distribution and elimination. The half-lives of the second phase were 26.7, 14.4, 14.1 and 11.6 minutes respectively. These were shorter than the half-lives reported for adult dogs, 32.6 and 27 minutes. 8 ,'2 Slower elimination in the young may be due to relatively less liver blood flow and/or immature metabolic enzyme activity in the newborn. The shorter half-lives might be the result of the shorter sampling period employed in the present study. The duration of sampling can influence the calculation of final half-lives. 'l - '4 The volumes of distribution were comparable to those reported by Nation and Triggs in human studies, 0.895 (SO 0.276) lIkg. '5 . These did not show any significant difference with age which was unexpected because the extracellular fluid compartment is relatively greater in the very young. 16 • 17 The lower values in younger dogs were therefore attributed to a reduced rate of elimination, as indicated by the age related changes in the elimination rate constant k 10.
